Interim Report April - December 2020
Continued growth during the third quarter.CEO’s comments The third quarter of 2020/21 was a stable quarter for EQL Pharma with slightly lower than average growth. Sales for the quarter, after a downward adjustment for non-recurring sales, amounted to SEK 23.4 million, an increase of 12%. Our goal is to become a leading player in niche generics in the Nordic region and eventually in Europe. To succeed in this, we need an agressive plan for rapid growth. The two principal components of this growth plan are geographical expansion of existing products and an increased number of new products.